Evaluation of Hemostatic Agents in Partial Nephrectomy: A Prospective Randomized Trial
Completed Not Applicable NCT07232927
Study Description
This prospective randomized study aims to evaluate the effect of adjunctive hemostatic agents (FloSeal® and Surgicel®) on perioperative outcomes in patients undergoing partial nephrectomy for localized renal tumors. A total of 150 patients were randomized into three groups: standard parenchymal suturing (Group A), suturing with FloSeal® (Group B), and suturing with Surgicel® (Group C). The study primarily investigates whether hemostatic agents reduce postoperative hemorrhage, urinary leakage, and positive surgical margin rates. Secondary outcomes include renal function change, operative and ischemia times, estimated blood loss, and hospital stay. All surgeries were performed by a single experienced surgeon at Ankara University Urology Department between January 2023 and December 2024.
Study Details
- Registry ID:
- NCT07232927
- Conditions:
- Partial Nephrectomy, Hemostatic Agents, Localized Renal Cell Carcinoma
- Phase:
- Not Applicable
- Target Enrollment:
- 150 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Ankara University Faculty of Medicine, Department of Urology
Ankara, Ankara, Turkey (Türkiye)
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.